David Baxter PhD
Late Founder
Restrictive ECT use 'not warranted'
Electroconvulsive therapy (ECT) improves mood, quality of life, and function in people with major depression, say US investigators who suggest that a restrictive attitude towards this therapy is unwarranted.
"Guidance on the use of ECT in the UK issued by the National Institute for Clinical Evidence recommended sharp restrictions on the use of this therapy until more information becomes available about its effects on memory, quality of life, and other pertinent health outcomes," explain W Vaughn McCall and colleagues from Wake Forest University Health Sciences in Winston-Salem, North Carolina.
To address this issue, the researchers measured changes in quality of life, function, mood, and cognition in 77 depressed patients before they received ECT and again 2 weeks and 4 weeks after completing treatment.
Overall, 66% of the patients responded to ECT, with improvement seen in every measure of mood, cognition, quality of life, and function at both the 2-week and 4-week assessments.
Interestingly, improvement in quality of life was related to mood, whereas improved ability to carry out activities of daily living was related to enhanced global cognition.
Comparing test results before and after ECT for patients who responded to treatment showed statistically significant differences on nine of the 10 psychological tests, the researchers note in the British Journal of Psychiatry.
The only decline was seen on the autobiographical memory test, but the researchers stress that this test is designed to show memory loss rather than improvement.
"The results are consistent with the premise that ECT produces a net improvement in health for most patients, and should help fill in the knowledge gap that led to the restrictive guidance on the use of ECT in the UK," say McCall and team.
Br J Psychiatry 2004; 185: 405-409
Electroconvulsive therapy (ECT) improves mood, quality of life, and function in people with major depression, say US investigators who suggest that a restrictive attitude towards this therapy is unwarranted.
"Guidance on the use of ECT in the UK issued by the National Institute for Clinical Evidence recommended sharp restrictions on the use of this therapy until more information becomes available about its effects on memory, quality of life, and other pertinent health outcomes," explain W Vaughn McCall and colleagues from Wake Forest University Health Sciences in Winston-Salem, North Carolina.
To address this issue, the researchers measured changes in quality of life, function, mood, and cognition in 77 depressed patients before they received ECT and again 2 weeks and 4 weeks after completing treatment.
Overall, 66% of the patients responded to ECT, with improvement seen in every measure of mood, cognition, quality of life, and function at both the 2-week and 4-week assessments.
Interestingly, improvement in quality of life was related to mood, whereas improved ability to carry out activities of daily living was related to enhanced global cognition.
Comparing test results before and after ECT for patients who responded to treatment showed statistically significant differences on nine of the 10 psychological tests, the researchers note in the British Journal of Psychiatry.
The only decline was seen on the autobiographical memory test, but the researchers stress that this test is designed to show memory loss rather than improvement.
"The results are consistent with the premise that ECT produces a net improvement in health for most patients, and should help fill in the knowledge gap that led to the restrictive guidance on the use of ECT in the UK," say McCall and team.
Br J Psychiatry 2004; 185: 405-409